Precision Business Insights


Research Reports

Databank $ 3,000.00
Single User $ 4,400.00
Multiple User $ 6,600.00
Corporate User $ 8,900.00
buy now spinner

Why Precision Business Insights?

  • Pre and Post Sale Support

    Get in touch with our industry experts to resolve your research queries before and after buying the report. Avail free 60 minutes analyst tele-call to get additional market information before and after purchase

  • Special Pricing and Discounts

    Avail special pricing for the purchase of report sections,regional insights, and historical data. Discounts for government bodies, research institutes, universities, NGO’s and start-up’s

  • In-depth Market Analysis

    Our research reports provides holistic market information with 360 degree analysis. We adopt 3 pronged strategy to analyze the market i.e. Secondary research , primary research, and expert validation

  • Accurate and Reliable Market Data

    Utmost focus on delivering accurate and reliable research reports. We adopt internally developed data mining tools to eliminate any data errors


    Proven expertise in delivering new and emerging markets product and technology advancements. We provide market information across the developed and emerging markets


    We provide impeccable research reports in quick turnaround time

Pulmonary Embolism Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024

Pulmonary Embolism Treatment Market by drug class (Anticoagulant, Thrombolytics), By route of administration (Oral, Intravenous, Subcutaneous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography.

Available formats:    


Pulmonary Embolism Treatment Market Outline


Pulmonary embolism is a blockage in pulmonary arteries in lungs. The cause of blockage is usually a blood clot. The clots are observed to be small and are not harmful, but they can damage the lungs due to restricted blood flow, decrease oxygen levels in the blood, and affect other organs as well. As the clot blocks the blood flow to the lungs, pulmonary embolism can be life-threatening. However, prompt treatment could save your life or reduce the risk of future problems. The major aim of treatment is to break up clots and avoid the formation of clots. Pulmonary embolism (PE) is treated with medicines, procedures, and other therapies.


Increase in the incidence of cancer, surge in cardiac disorders are expected to increases the pulmonary embolism. The growth in the number of cancer patients is expected to increase the revenue share of the market. Rise in the aging population, increasing obesity problems enable fuel the growth of the market. However, introduction of novel oral anticoagulants and the high cost for the treatment are expected to hamper the growth of the market.


Global Pulmonary Embolism Treatment market was valued at US $ XX Mn and expected to grow at XX% Compound Annual Growth Rate (CAGR) over 2018 to 2024


Pulmonary Embolism Treatment Market Scope


The market is segmented based on the drug class, route of administration, and distribution channel

Based on the drug class, the market is segmented into the following:

  • Anticoagulant
    • Warfarin
    • Heparin
    • Low molecular-weight heparin
    • Fondaparinux (Arixtra)
    • Other
  • Thrombolytics
    • Reteplase
    • Alteplase
    • Others

Based on the route of administration, the market is segmented into the following:

  • Oral
  • Intravenous
  • Subcutaneous


Based on the distribution channel, the market is segmented into the following:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies


Global Pulmonary Embolism Treatment Market Regional Analysis


Geographically, global pulmonary embolism treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America dominated the market due to high medical reimbursement facilities, and technological advancements. However, Asia Pacific pulmonary embolism treatment market is forecasted to have the fastest growth, owing to a rapidly increasing population, rise in patient awareness, favorable government policies, and modernization of healthcare infrastructure. The growth in the medical tourism industry is expected to boost the growth of market in the Asia Pacific region.


Competition Assessment: Pulmonary Embolism Treatment Market


  • Accu-Break Pharmaceuticals Inc (U.S)
  • Daiichi Sankyo Company Ltd (Japan)
  • Dong-A Socio Holdings Co Ltd (South Korea)
  • Hoffmann-La Roche Ltd (Switzerland)
  • Genentech Inc (U.S)
  • Janssen Pharmaceuticals, Inc (Belgium)
  • Verseon Corp (U.S)


Notable Market Developments:


In November 2012, Janssen Pharmaceuticals, Inc. (Janssen) announced the U.S. Food and Drug Administration (FDA) has approved XARELTO (rivaroxaban), an oral anticoagulant, for the treatment of deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and to reduce the risk of recurrence of DVT and PE following initial treatment


Key Features of the Report:

  • The report covers exhaustive regional information, that includes North America (the USA and Canada), Europe (Germany, France, Italy, UK, Spain, Russia, Poland and Rest of Europe), Asia-Pacific (Japan, China, India, Australia & New Zealand, ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others), South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentian, Venezula, and Rest of Latin America), and Middle East and Africa (Gulf Cooperation Council (GCC) Countries, Israel, South Africa, and Rest of Middle East and Africa)
  • The report provides granular level information about the market size, regional market share, historic market (2013-2017) and forecast (2018-2024)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
  • Accu-Break Pharmaceuticals Inc (U.S)
  • Daiichi Sankyo Company Ltd (Japan)
  • Dong-A Socio Holdings Co Ltd (South Korea)
  • Hoffmann-La Roche Ltd (Switzerland)
  • Genentech Inc (U.S)
  • Janssen Pharmaceuticals, Inc (Belgium)
  • Verseon Corp (U.S)

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements


Avail Discount  Up To 20%

Need more discount on this report?

Call or e-mail us for:

(U.S.) – +1-866-598-1553

Contact SalesTOLL FREE: +1-866-598-1553